Voy at-home test kit ads banned for false low testosterone claims

Photo of author

By Elena Vasquez

Online healthcare provider Voy has been ordered to withdraw a series of adverts promoting its at-home testosterone test kits after the Advertising Standards Authority (ASA) ruled that the ads made misleading claims about low testosterone symptoms in men. The decision highlights growing concerns about the marketing of health tests that may prey on common anxieties without sufficient scientific backing.

How Voy’s Ads Misrepresented Testosterone Deficiency

Voy’s advertisements appeared in multiple formats, including posters and paid Facebook ads, and linked everyday symptoms such as irritability, fatigue, low energy, and mood changes directly to low testosterone levels. The ASA found this connection was exaggerated and not supported by robust evidence. The regulator emphasized that while some symptoms like reduced sex drive and erectile dysfunction can sometimes be linked to testosterone deficiency, many of the signs promoted by Voy are nonspecific and can arise from a wide range of causes unrelated to hormone levels.

One Facebook ad claimed that “low testosterone sneaks up on 1 in 4 men over 30,” a statement the ASA found misleading due to lack of credible data. Such claims risk creating unnecessary alarm among men who experience common life stresses or aging-related changes, potentially driving them toward unnecessary testing or treatments.

The Broader Context of Testosterone Testing and Men’s Health Marketing

The ASA’s ruling against Voy is part of a wider crackdown on online health advertisers targeting men’s insecurities around ageing, libido, and hormone levels. Earlier this year, similar bans were issued against other providers like BioID Health and Numan Digital Healthcare for overstating the prevalence and impact of low testosterone.

Testosterone levels naturally decline with age, but the NHS states this decline rarely causes significant problems on its own. While testosterone deficiency can contribute to symptoms such as depression or loss of sex drive, these symptoms are often multifactorial. Experts caution that blood tests for testosterone are sensitive to timing, health status, and even recent meals, making isolated results difficult to interpret reliably.

Dr. Richard Quinton, a specialist in testosterone deficiency, notes that low readings can easily occur in healthy men depending on when and how the test is taken. This complexity underscores the risks of direct-to-consumer testing without thorough clinical assessment.

Implications for Consumers and the Healthcare Industry

Voy’s decision to withdraw the adverts during the ASA investigation suggests a recognition of the need for more responsible marketing in the burgeoning online health testing market. However, the persistence of such adverts reflects a broader challenge: balancing consumer access to convenient health tools with the imperative to provide accurate, evidence-based information.

For men experiencing symptoms like fatigue or mood changes, the ASA’s ruling serves as a reminder that these signs are not necessarily indicative of low testosterone and should prompt consultation with qualified healthcare professionals rather than reliance on at-home tests alone.

The controversy also raises questions about the regulation of health claims in digital advertising, especially for conditions that are complex and often stigmatized. As companies like Voy expand their offerings in hormone therapies and related products, regulators must remain vigilant to ensure that marketing does not exploit vulnerabilities or oversimplify medical science.

Looking Ahead: The Need for Clearer Standards

As awareness of men’s health issues grows, so does the market for related diagnostic and treatment services. The ASA’s actions signal a tightening of standards to curb misleading claims and protect consumers from potentially unnecessary or harmful interventions.

Going forward, healthcare providers and advertisers will need to ground their messaging in solid clinical evidence and transparent communication. This approach not only safeguards public trust but also supports men in making informed decisions about their health without falling prey to sensationalized or inaccurate claims.

Recommended reading

For more context, see related Peack News coverage and explainers linked below.

Editor's note

Editors added context and linked coverage to make the story more useful than a standalone feed item. This page also reflects material updates made after publication.

Article briefing

The decision highlights growing concerns about the marketing of health tests that may prey on common anxieties without sufficient scientific backing.

Story details

  • Author: Elena Vasquez
  • Published: November 18, 2026
  • Updated: November 18, 2026
  • Category: Health

Key developments

  • Voy’s advertisements appeared in multiple formats, including posters and paid Facebook ads, and linked everyday symptoms such as irritability, fatigue, low energy, and mood changes directly to low testosterone levels.
  • The ASA found this connection was exaggerated and not supported by robust evidence.
  • One Facebook ad claimed that “low testosterone sneaks up on 1 in 4 men over 30,” a statement the ASA found misleading due to lack of credible data.

Why this matters

The decision highlights growing concerns about the marketing of health tests that may prey on common anxieties without sufficient scientific backing.

Impact and next steps

Voy’s decision to withdraw the adverts during the ASA investigation suggests a recognition of the need for more responsible marketing in the burgeoning online health testing market.

Source

This article is based on source material from BBC News.

About the author

Elena Vasquez

Elena Vasquez writes about health, lifestyle, travel and entertainment. A former magazine editor, she brings a distinctive voice to consumer wellness, cultural trends and destination guides, drawing on years of on-the-ground reporting across four continents.

editorial@peacknews.com